Sign In
Buy BHVN
$13.50
-0.320 (-2.32%)
At Close: Jul 31, 2026
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
04:05pm, Wednesday, 02'nd Oct 2024
NEW HAVEN, Conn. , Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
06:00am, Tuesday, 01'st Oct 2024
NEW HAVEN, Conn. , Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Proposed Public Offering of Common Shares
04:05pm, Monday, 30'th Sep 2024
NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
07:30am, Monday, 30'th Sep 2024
Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent, orally administered Transient Receptor Potential Melas
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
11:56am, Tuesday, 24'th Sep 2024
The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
10:42am, Tuesday, 24'th Sep 2024
Biohaven Ltd. NYSE: BHVN has taken center stage in the biopharmaceutical sector after releasing positive results from its Phase 3 clinical trial for troriluzole, a drug being developed to treat spinoc
Overlooked Stock: BHVN
05:02pm, Monday, 23'rd Sep 2024
Biohaven (BHVN) shares surged after the company's troriluzole drug showed significant slowed progression of spinocerebellar ataxia, a rare neurological disease. George Tsilis shares how the promising
Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst
02:55pm, Monday, 23'rd Sep 2024
Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with spinocerebellar ataxia; the Drug achieved 50% to 70% of slowing of disease progression
Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug
02:40pm, Monday, 23'rd Sep 2024
Biohaven (BHVN) shares soared 15% Monday after the biotech firm announced positive results from a study of its experimental treatment for a rare neurological condition.
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise
11:22am, Monday, 23'rd Sep 2024
Monday, Biohaven Ltd. BHVN released topline results from pivotal Study BHV4157-206-RWE demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after three years of tr
Biohaven's stock surges as treatment slows progress of neurological disorder
09:18am, Monday, 23'rd Sep 2024
Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed progress of the condition in a clinical trial.
Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease
09:11am, Monday, 23'rd Sep 2024
Biohaven stock jumped Monday after the company's experimental drug slowed progression in a rare disease with no approved treatments.
Biohaven's genetic disease drug meets main trial goal
08:03am, Monday, 23'rd Sep 2024
Biohaven has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly affects the brain, the company said on Monday.
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
07:30am, Monday, 23'rd Sep 2024
Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia
Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
07:09pm, Friday, 20'th Sep 2024
Conference call and webcast to be held Monday, September 23, at 8:30am ET NEW HAVEN, Conn. , Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd.
